Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1326 ARTÍCULOS , VIENDO DEL 181 AL 195

[Alzheimer's disease]

Hanyu H, Sato T.

Nihon Rinsho. 2010 Feb;68(2):330-4.

Gene therapy in Alzheimer's disease - potential for disease modification

Nilsson P, Iwata N, Muramatsu S, Tjernberg LO, Winblad B, Saido TC.

J Cell Mol Med. 2010 Apr;14(4):741-57. doi: 10.1111/j.1582-4934.2010.01038.x. Epub 2010 Feb 16.

Are Abeta and its derivatives causative agents or innocent bystanders in AD?

Robakis NK.

Neurodegener Dis. 2010;7(1-3):32-7. doi: 10.1159/000266476. Epub 2010 Feb 13.

p53 is regulated by and regulates members of the gamma-secretase complex

Checler F, Dunys J, Pardossi-Piquard R, Alves da Costa C.

Neurodegener Dis. 2010;7(1-3):50-5. doi: 10.1159/000283483. Epub 2010 Feb 13.

Ginkgo biloba extract in Alzheimer's disease: from action mechanisms to medical practice

Shi C, Liu J, Wu F, Yew DT.

Int J Mol Sci. 2010 Jan 8;11(1):107-23. doi: 10.3390/ijms11010107.

Assessment of white matter tract damage in mild cognitive impairment and Alzheimer's disease

Pievani M, Agosta F, Pagani E, Canu E, Sala S, Absinta M, Geroldi C, Ganzola R, Frisoni GB, Filippi M.

Hum Brain Mapp. 2010 Dec;31(12):1862-75. doi: 10.1002/hbm.20978. Epub 2010 Feb 16.

An Alzheimer disease presenilin mutation, syndrome diversity, and a shrinking world

Swerdlow RH.

Neurology. 2010 Mar 9;74(10):790-1. doi: 10.1212/WNL.0b013e3181d3e429. Epub 2010 Feb 17.

Radiofrequency fields, transthyretin, and Alzheimer's disease

Söderqvist F, Hardell L, Carlberg M, Mild KH.

J Alzheimers Dis. 2010;20(2):599-606. doi: 10.3233/JAD-2010-1395.

PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses

Faux NG, Ritchie CW, Gunn A, Rembach A, Tsatsanis A, Bedo J, Harrison J, Lannfelt L, Blennow K, Zetterberg H, Ingelsson M, Masters CL, Tanzi RE, Cummings JL, Herd CM, Bush AI.

J Alzheimers Dis. 2010;20(2):509-16. doi: 10.3233/JAD-2010-1390.

Oxidatively modified glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and Alzheimer's disease: many pathways to neurodegeneration

Butterfield DA, Hardas SS, Lange ML.

J Alzheimers Dis. 2010;20(2):369-93. doi: 10.3233/JAD-2010-1375.

Effects of estrogen in the brain: is it a neuroprotective agent in Alzheimer's disease?

Correia SC, Santos RX, Cardoso S, Carvalho C, Santos MS, Oliveira CR, Moreira PI.

Curr Aging Sci. 2010 Jul;3(2):113-26. doi: 10.2174/1874609811003020113.

Lipid mediators in the nucleus: Their potential contribution to Alzheimer's disease

Farooqui AA, Ong WY, Farooqui T.

Biochim Biophys Acta. 2010 Aug;1801(8):906-16. doi: 10.1016/j.bbalip.2010.02.002. Epub 2010 Feb 17.

Elevated ratio of urinary metabolites of thromboxane and prostacyclin is associated with adverse cardiovascular events in ADAPT

Montine TJ, Sonnen JA, Milne G, Baker LD, Breitner JC.

PLoS One. 2010 Feb 19;5(2):e9340. doi: 10.1371/journal.pone.0009340.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias